Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.48 |
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233928 | 1.00 | CACNA1B (0.48) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL192185 | 1.00 | CACNA1B (0.48) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL30089915 | 0.99 | CACNA1B (0.48) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL6842296 | 0.99 | CACNA1B (0.48) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL26895103 | 0.90 | CACNA1B (0.53) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL29050985 | 0.89 | CACNA1B (0.53) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL29050983 | 0.89 | CACNA1B (0.53) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL14066376 | 0.88 | CACNA1B (0.44) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL26296033 | 0.87 | CACNA1B (0.49) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL12332835 | 0.87 | CTSK (0.50) | CACNA1BCTSKCTSSHDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636409-B2 | Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20140088159-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2014-03-27 | — | — | US | disclosed |
| EP-2079743-B1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | c/o Chroma Therapeutics Ltd. (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
| WO-2010043867-A1 | PYRROLO [2, 3-D] PYRIMIDINES AS INHIBITORS OF HSP90 | CHROMA THERAPEUTICS LTD (GB) | 2010-04-22 | — | — | WO | disclosed |
| WO-2008053157-A1 | AMINOHETEROARYL COMPOUNDS AS FOR THE TREATMENT OF DISEASES MEDIATED BY C-MET KINASE ACTIVITY | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088159-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | CACNA1B 3409/4885CTSK 736/4885CTSS 503/4885 |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | CACNA1B 3409/4885CTSK 736/4885CTSS 503/4885 |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | CACNA1B 3409/4885CTSK 736/4885CTSS 503/4885 |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | CACNA1B 4712/4885CTSK 983/4885CTSS 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.